CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioSpace
Original article

Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates

Positive
AI Analysis

Summary

Eli Lilly acquired AtaiBeckley for $3.8 billion in a psychedelics-focused deal that validates the drug class but is unlikely to trigger broader Big Pharma acquisition activity in the sector.

Importance:7/10
Sentiment:
0.30
M&ApsychedelicsacquisitionBig Pharma
Related Companies

Read the original article

Published by BioSpace on July 24, 2026 12:10 PM

Read Original